The startup develops exosome-based diagnostic devices that enhance liquid biopsy by identifying organ-specific disease signatures. This technology enables early cancer detection through minimally invasive methods, providing healthcare providers with actionable clinical data for effective treatment planning.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for obtaining tissue samples for disease diagnosis often require invasive procedures like biopsies. Analyzing exosomes, small vesicles released by cells into bodily fluids, holds promise for non-invasive disease detection, but their small size and complex nature make them difficult to isolate and analyze effectively.
Solution
Chip Diagnostics is developing a platform for exosome-based liquid biopsies, enabling minimally invasive disease detection and monitoring. Their microDroplet Fluorescence Detector (µDFD) platform uses a hybrid microelectronic/microfluidic chip to analyze millions of exosomes in parallel from a blood sample. The platform employs a proprietary workflow to identify and interpret organ-specific exosome populations, providing a fingerprint of disease states. This approach offers a less time and resource-intensive workflow for disease diagnostics and therapy management.
Target Audience
The primary customers are biopharmaceutical companies and diagnostic firms involved in drug discovery and disease diagnostics.
Features
- microDroplet Fluorescence Detector (µDFD) platform for high-throughput exosome analysis
- Hybrid microelectronic/microfluidic chip enabling digital assays
- Proprietary workflow for isolating and analyzing tissue-specific exosomes
- Fluorescence digitalization using amplitude modulation for ultrasensitive detection
- AI-driven data informatics platform for disease fingerprinting
- Compatible with downstream workflows such as NGS, PCR, and ELISA